Edition:
United States

People: Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

10.16USD
24 May 2019
Change (% chg)

$-0.12 (-1.17%)
Prev Close
$10.28
Open
$10.35
Day's High
$10.51
Day's Low
$9.81
Volume
1,055,528
Avg. Vol
848,747
52-wk High
$36.35
52-wk Low
$9.58

Blank, Burkhard 

Dr. Burkhard Blank M.D. is Chief Medical Officer of the Company. Prior to that, from January 2016 to June 2016, Dr. Blank was engaged by the Company to assume chief medical officer responsibilities on an interim basis. Dr. Blank has more than 26 years of experience in the pharmaceutical industry. Prior to working for the Company, from June 2014 to June 2016, Dr. Blank was the Chief Medical Officer of Herantis Pharma. From June 2013 to May 2014 he was the Chief Executive Officer of Laurantis Pharma and from June 2012 to May 2013 Dr. Blank acted as a consulting chief medical officer. Prior thereto, from October 2010 to June 2012, Dr. Blank served as a consulting chief medical officer for Mersana Therapeutics. Dr. Blank previously consulted as chief medical officer and served in various medical leadership roles for several biopharmaceutical companies, including Inhibikase Pharmaceuticals, Qwell Pharmaceuticals, New Haven Pharmaceuticals, Alnara Pharmaceuticals, Altus Pharmaceuticals, and Boehringer Ingelheim (BI). While at BI, he oversaw the submission of five New Drug Applications (NDAs) and had direct responsibility for all aspects of presenting at two FDA Advisory Committee Meetings; and subsequently, all five NDAs received FDA approval. Dr. Blank has also served as a strategic advisor to several biotechnology companies, leading the submission process for multiple Investigational Drug Applications (INDs), successfully developing protocols for clinical trial programs, and overseeing communications with regulatory agencies. Dr. Blank serves on the Board of Directors of Riemser Pharma GmbH. Dr. Blank received his medical degree from Universitaet Marburg, Germany. He is board-certified in Germany in internal medicine.

Basic Compensation

Total Annual Compensation, USD 662,360
Restricted Stock Awards, USD 288,488
Long-Term Incentive Plans, USD --
All Other, USD 526,721
Fiscal Year Total, USD 1,477,570

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Ron Cohen

2,016,980

Richard Batycky

--

David Lawrence

999,491

Jane Wasman

1,986,540

Burkhard Blank

1,477,570

Andrew Hindman

1,605,310
As Of  30 Dec 2017